HireRight now offers COVID-19 viral marker (molecular via RT-PCR) assurance testing, as well as new referral options through Preworkscreen and CIC Health.
These additional capabilities build on the company's ad hoc COVID-19 solution for symptomatic or exposed individuals to help employers screen large workforce populations to help prevent the spread of contagion.
HireRight's COVID-19 screening solutions includes ad hoc testing through a COVID-19 viral marker test option that has been authorized by the FDA under Emergency Use Authorization.
Employers can elect to order a COVID-19 viral marker test through the HireRight platform.
The test detects the presence of coronavirus in the saliva of the test taker. Unlike blood draws or nasal swabs, the saliva sample is easily self-collected and is not technique dependent.
Assurance testing offers the same COVID-19 viral marker test that has been authorized by the FDA under Emergency Use Authorization, offered at periodic intervals for the entire workforce, usually at least once per week.
This widespread testing of healthy people allows employers to return to full operations by helping identify cases of COVID-19 early especially among employees who are either pre-symptomatic or asymptomatic without outward signs of infection versus testing programs that focus on the testing of individuals who are symptomatic or who have suspected exposure to COVID-19.
A COVID-19 Self-Assessment Tool through Preworkscreen to offer a simple and efficient way to conduct employee COVID-19 symptom questionnaires that aligns with CDC/State guidelines, the company said.
Each day before work, employees complete the assessment on their mobile device of choice. Results are compiled in real-time and immediately available, so you can quickly track and monitor the overall health status of your workforce.
Additionally, in order to make cost effective, fast turn-around assurance testing available to larger enterprises, we are partnering with CIC Health, a leader in creating COVID-19 testing programs.
Along with a full-service, low-cost testing solution from a nationwide network of laboratories, CIC Health can manage needed collectors and medical oversight of testing results.
HireRight has provided customers with guidance and assistance concerning various challenges arising as a result of the COVID-19 crisis.
With the launch of these additional screening options, HireRight furthers our partnership for our clients by offering a range of COVID-19 viral marker test options that have been authorized by the FDA under Emergency Use Authorization.
HireRight offers employers global employment background checks, drug testing, education verification, E-Verify solutions, and other workforce solutions.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval